Clinical trials: Alopecia Areata, open to volunteers
Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced), Alopecia Areata
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
Background: Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) is a problem of the immune system. In people with APECED, the immune system makes a mistake and attacks the body.
- Trial name
- NCT05398809
- Testing
- Ruxolitinib
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Severe Alopecia Areata
A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the scalp and face, but hair loss can happen on any hair-bearing part of the body.
- Trial name
- NCT07772492
- Testing
- Upadacitinib
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 300 people
- Sponsor
- AbbVie
Alopecia Areata
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of alopecia areata.
- Trial name
- ALLEGRO-100 (NCT06873945)
- Testing
- Ritlecitinib 100 mg, Ritlecitinib 50 mg
- Where
- 148 sites in United States, Canada and 9 more
- Volunteers
- 674 people
- Sponsor
- Pfizer
Alopecia Areata
A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia Areata
This study is a multicenter, open-label, non-randomized, dose-finding Phase I study designed to evaluate the pharmacokinetics (PK), safety, and preliminary efficacy of VC005 tablets in adolescent subjects with severe alopecia…
- Trial name
- NCT07762443
- Testing
- VC005 tablets
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Alopecia Areata
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and face, but hair loss can happen on any part of the body.
- Trial name
- Up-AA (NCT06012240)
- Testing
- Upadacitinib
- Where
- 272 sites in United States, Argentina and 26 more
- Volunteers
- 1,500 people
- Sponsor
- AbbVie
Atopic Dermatitis, Alopecia Areata
Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome
This is a single-center, open-label, basket phase 2b trial that will enroll Down Syndrome (DS) participants with at least one inflammatory skin condition (Atopic Dermatitis (AD) and/or Alopecia Areata (AA)).
- Trial name
- NCT07242638
- Testing
- Abrocitinib
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Severe Alopecia Areata
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
The purpose of this clinical trial is to learn about long-term safety and long-term effects of the study medicine (called ritlecitinib) for the potential treatment of severe alopecia areata, a condition that causes hair loss.
- Trial name
- B7981028 (NCT07029828)
- Testing
- Ritlecitinib higher dose, Ritlecitinib lower dose
- Where
- 67 sites in United States, China and 7 more
- Volunteers
- 140 people
- Sponsor
- Pfizer
Alopecia Areata
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata
This study evaluates the efficacy and safety of deuruxolitinib in Japanese Adults between 18 and 65 years of age who have 50% or greater scalp hair loss.
- Trial name
- THRIVE-AAJP (NCT07617597)
- Testing
- Deuruxolitinib
- Where
- 18 sites in Japan
- Volunteers
- 78 people
- Sponsor
- Sun Pharma Japan Limited
Alopecia Areata
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
The purpose of this study is to evaluate how well LY4005130 works in participants with severe alopecia areata (hair loss) when compared with placebo, and how well it's tolerated and what side effects may occur.
- Trial name
- NCT07533006
- Testing
- LY4005130
- Where
- 30 sites in United States, Canada and 5 more
- Volunteers
- 60 people
- Sponsor
- Eli Lilly and Company
Alopecia Areata
Comparison of Topical Calcipotriol and Intralesional Steroids in Alopecia Areata
This randomized controlled trial compares the effectiveness of topical calcipotriol and intralesional corticosteroids in the treatment of alopecia areata.
- Trial name
- CALISTA-AA (NCT07453238)
- Testing
- Calcipotriol, Triamcinolone Acetonide
- Volunteers
- 60 people
- Sponsor
- Hayat Abad Medical Complex, Peshawar
Alopecia Areata(AA)
HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata
This is a Phase 1, open-label, multi-center, competitive enrollment, and dose-escalation study of HCW9302 in subjects with Alopecia Areata (AA)
- Trial name
- IL-2 (NCT07049328)
- Testing
- HCW9302, an IL-2 fusion protein
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- HCW Biologics
Alopecia Areata
UV-Trichoscopic Red Fluorescence in Alopecia Areata
The goal of this observational study is to learn whether red fluorescence seen with ultraviolet (UV) trichoscopy is related to disease findings and treatment response in adults with limited plaque-type alopecia areata.
- Trial name
- NCT07803874
- Testing
- Triamcinolone Acetonide
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Istanbul Training and Research Hospital
Alopecia Areata
A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the potential treatment of moderate alopecia areata (AA).
- Trial name
- NCT07733765
- Testing
- Ritlecitinib 100 mg, Ritlecitinib 50 mg
- Where
- 20 sites in United States, Canada and 1 more
- Volunteers
- 336 people
- Sponsor
- Pfizer
Vitiligo, Atopic Dermatitis
An Observational Study of Patients With Dermatologic Disease
TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients.
- Conditions
- Vitiligo, Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa (HS)
- Trial name
- TARGET-DERM+ (NCT07748169)
- Where
- United States
- Volunteers
- 2,000,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Areata Alopecia, Alopecia
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age.
- Conditions
- Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases
- Trial name
- BRAVE-AA-PEDS (NCT05723198)
- Testing
- Baricitinib
- Where
- 127 sites in United States, Argentina and 10 more
- Volunteers
- 595 people
- Sponsor
- Eli Lilly and Company
Alopecia Areata
Dupilumab in the Treatment of Pediatric Alopecia Areata
This is a prospective, randomized, double-blind, placebo-controlled clinical trial. The study will take place at four sites. This trial will enroll a total of 76 children and adolescents with moderate to severe AA (affecting at…
- Trial name
- PEDAL (NCT05866562)
- Testing
- Dupilumab
- Where
- 5 sites in United States
- Volunteers
- 76 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Atopic Dermatitis, Psoriasis
Determinants of Chronic Inflammatory Skin Disease Trajectories
Although it is well known that the clinical expression and course of chronic inflammatory skin diseases are highly variable, there are insufficient epidemiological data on this, and the factors that determine the manifestation…
- Conditions
- Atopic Dermatitis, Psoriasis, Lichen Planus, Alopecia Areata
- Trial name
- NCT05928169
- Testing
- Topical and systemic drugs
- Where
- Germany
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University Hospital Schleswig-Holstein
Alopecia Areata
Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata
This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study designed to evaluate the efficacy and safety of VC005 tablets in subjects with severe alopecia areata (AA).
- Trial name
- NCT07749716
- Testing
- Drug: VC005 tablets, VC005 tablets
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Alopecia Areata
CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry
Prospective observational registry focusing on an adolescent cohort diagnosed with severe alopecia areata,receiving routine care from dermatology providers.
- Trial name
- NCT06562270
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- CorEvitas
Alopecia Areata(AA), Alopecia Areata
Serum Ferroptosis Biomarkers (GPX4, MDA) in Alopecia Areata
This study aims to investigate the potential role of the ferroptosis pathway in the pathogenesis and clinical course of Alopecia Areata (AA).
- Conditions
- Alopecia Areata(AA), Alopecia Areata, Alopecia Areata (& Ophiasis), Alopecia
- Trial name
- NCT07733063
- Where
- Turkey (Türkiye)
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Istanbul Training and Research Hospital